NEW YORK, July 22, 2026, 10:20 EDT – Shares of Lakewood-Amedex NASDAQ:LABT soared following an update on its Nu-3 program, as trading volume surged to over 200 times the usual daily average.
- U.S. markets were open for standard trading. LABT rose 143.5% to $4.53 as of 10:05 EDT.
- Volume was reported at 58.1 million shares, roughly 232 times higher than its posted average.
- The main resistance test was initially introduced on May 1. No new patient data were included in Wednesday’s update.
Lakewood-Amedex Biotherapeutics Inc. NASDAQ:LABT surged 143.5% to reach $4.53 at 10:05 a.m. EDT, after hitting a session high of $7.13 earlier.
Shares traded at 58.1 million, roughly 232 times the visible average. The SPDR S&P Biotech ETF (NYSEARCA:XBI) slipped 0.6%.
The gap is significant for investors, indicating this is a company-driven development rather than a sector-wide surge in biotech stocks.
The key divide remains between price and updated evidence. The statement released Wednesday reiterated the core 21-day test initially outlined on May 1.
Early intraday data reveal the extent of the response:
| Signal | Lakewood reading | Base or benchmark |
|---|---|---|
| Day change | +143.5% | XBI: -0.6% |
| Volume reported | 58.1 million | 232x the shown average |
| Turnover calculation | 33.2x | June post-split total: near 1.75 million |
| Drop from high to latest | -36.5% | $7.13 high vs $4.53 latest |
The turnover ratio is based on Lakewood’s June filing, listing the post-split amount at approximately 1.75 million. Trading on a split-adjusted basis started on June 22. This figure is an initial estimate, as subsequent conversions could raise the present total.
Nu-3’s minimum inhibitory concentration for E. coli increased modestly in May. No change was observed for MRSA. Control groups treated with ciprofloxacin demonstrated increases in resistance of over 2,000-fold and 600-fold, respectively.
The Wednesday update included the addition of a policy link and expanded in-vitro profiling, outlining activity across multiple resistance mechanisms. No additional patient data were presented.
Nu-3 “targets and disrupts bacterial membranes through a unique, physical mechanism of action,” according to Chief Executive Kelvin Cooper. The backing for this statement is still laboratory-based. PR Newswire
PACCARB, the federal advisory council, convened on June 16. According to HHS, it contributed recommendations for the government’s action plan covering 2026-2031. The formal summary outlines both the discussions and guidance provided.
According to management’s initial schedule, the first patient visit is planned for the third quarter. Top-line results from the Phase 2a study are expected by late 2026 or in early 2027.
As of March 31, Lakewood’s cash balance stood at $11,709. The company also raised roughly $6.8 million net from convertible preferred stock proceeds. According to management, this funding is expected to sustain operations through 2026.
Risks stay elevated. Data from the next patient group in Phase 2a is still pending. There is a possibility that preclinical results will not carry over, and favourable conversions could result in dilution for shareholders.
The next significant challenge for investors will be clinical performance. Wednesday’s session saw heavy trading volumes, though fresh data on human efficacy was absent.
